Early surgery after coronary revascularization: a fine line between bleeding and thrombosis

Area of Science:

• Cardiology
• Interventional Cardiology
• Pharmacology

Background:

• Patients undergoing percutaneous coronary intervention (PCI) often require dual antiplatelet therapy (DAPT) to prevent stent thrombosis (ST).
• An increasing number of patients require early surgical intervention after PCI, creating a clinical dilemma regarding antiplatelet management.
• Balancing the risk of bleeding versus thrombotic events is critical in this patient population.

Purpose of the Study:

• To review current guidelines for managing DAPT in patients undergoing early surgery after PCI.
• To discuss optional strategies aimed at reducing cardiovascular risk in this setting.
• To provide insights into optimizing antiplatelet therapy management post-PCI before surgery.

Main Methods:

• Literature review of current guidelines and relevant studies.
• Discussion of therapeutic strategies for managing dual antiplatelet therapy (DAPT).
• Analysis of cardiovascular risk mitigation in patients with PCI undergoing early surgery.

Main Results:

• Current guidelines offer limited specific recommendations for managing DAPT in patients undergoing early surgery post-PCI.
• Various strategies exist to manage antiplatelet therapy, including drug cessation, bridging therapy, or continuation of single antiplatelet therapy.
• The optimal approach depends on individual patient risk factors, type of surgery, and urgency.

Conclusions:

• Management of DAPT in patients undergoing early surgery after PCI remains complex and requires individualized assessment.
• Further research is needed to establish definitive evidence-based guidelines for this high-risk patient group.
• Optimizing antiplatelet management is crucial for minimizing both bleeding and thrombotic complications.